DexCom Inc (DXCM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, DexCom Inc (DXCM) has a cash flow conversion efficiency ratio of 0.178x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($525.60 Million) by net assets ($2.96 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of DexCom Inc to measure how much of total assets are equity-financed.
DexCom Inc - Cash Flow Conversion Efficiency Trend (2003–2025)
This chart illustrates how DexCom Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check DXCM operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
DexCom Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of DexCom Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Power Grid Corporation of India Limited
NSE:POWERGRID
|
0.148x |
|
Yuanta Financial Holdings Co Ltd
TW:2885
|
-0.059x |
|
NARI Technology Co Ltd
SHG:600406
|
0.034x |
|
Asia Vital Components Co Ltd
TW:3017
|
0.271x |
|
TDK Corporation
F:TDKA
|
0.059x |
|
TRIP.COM GROUP DL-00125
F:CLVB
|
N/A |
|
Talanx AG
XETRA:TLX
|
0.183x |
|
Ares Management LP
NYSE:ARES
|
0.048x |
Annual Cash Flow Conversion Efficiency for DexCom Inc (2003–2025)
The table below shows the annual cash flow conversion efficiency of DexCom Inc from 2003 to 2025. For the full company profile with market capitalisation and key ratios, see DXCM stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $2.75 Billion | $1.44 Billion | 0.525x | +11.48% |
| 2024-12-31 | $2.10 Billion | $989.50 Million | 0.471x | +30.06% |
| 2023-12-31 | $2.07 Billion | $748.50 Million | 0.362x | +15.22% |
| 2022-12-31 | $2.13 Billion | $669.50 Million | 0.314x | +44.93% |
| 2021-12-31 | $2.04 Billion | $442.50 Million | 0.217x | -16.78% |
| 2020-12-31 | $1.83 Billion | $475.60 Million | 0.260x | -26.93% |
| 2019-12-31 | $882.60 Million | $314.50 Million | 0.356x | +91.85% |
| 2018-12-31 | $663.30 Million | $123.20 Million | 0.186x | -15.33% |
| 2017-12-31 | $419.40 Million | $92.00 Million | 0.219x | +10.77% |
| 2016-12-31 | $283.80 Million | $56.20 Million | 0.198x | -10.61% |
| 2015-12-31 | $221.20 Million | $49.00 Million | 0.222x | +31.60% |
| 2014-12-31 | $140.20 Million | $23.60 Million | 0.168x | +489.86% |
| 2013-12-31 | $84.10 Million | $2.40 Million | 0.029x | +106.64% |
| 2012-12-31 | $77.00 Million | $-33.10 Million | -0.430x | -49.10% |
| 2011-12-31 | $104.49 Million | $-30.13 Million | -0.288x | +58.79% |
| 2010-12-31 | $60.99 Million | $-42.68 Million | -0.700x | -132.76% |
| 2009-12-31 | $-18.45 Million | $-39.39 Million | 2.135x | +120.17% |
| 2008-12-31 | $-38.61 Million | $-37.45 Million | 0.970x | +120.78% |
| 2007-12-31 | $7.12 Million | $-33.21 Million | -4.667x | -506.45% |
| 2006-12-31 | $56.83 Million | $-43.73 Million | -0.770x | -68.61% |
| 2005-12-31 | $49.41 Million | $-22.55 Million | -0.456x | -281.09% |
| 2004-12-31 | $-49.31 Million | $-12.43 Million | 0.252x | -13.15% |
| 2003-12-31 | $-32.60 Million | $-9.46 Million | 0.290x | -- |
About DexCom Inc
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick bloo… Read more